MCID: DSS008
MIFTS: 70

Disease of Mental Health

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Disease of Mental Health

Summaries for Disease of Mental Health

MedlinePlus : 44 What is mental health? Mental health includes our emotional, psychological, and social well-being. It affects how we think, feel, and act as we cope with life. It also helps determine how we handle stress, relate to others, and make choices. Mental health is important at every stage of life, from childhood and adolescence through adulthood. What are mental illnesses? Mental illnesses are serious disorders which can affect your thinking, mood, and behavior. They may be occasional or long-lasting. They can affect your ability to relate to others and function each day. Mental disorders are common; more than half of all Americans will be diagnosed with a mental disorder at some time in their life. But there are treatments. People with mental health problems can get better, and many of them recover completely. Why is mental health important? Mental health is important because it can help you to Cope with the stresses of life Be physically healthy Have good relationships Make meaningful contributions to your community Work productively Realize your full potential How can I improve my mental health? There are steps you can take to help you improve your mental health. They include Staying positive Being physically active Connecting with others Developing a sense of meaning and purpose in life Getting enough sleep Developing coping skills Meditating Getting professional help if you need it

MalaCards based summary : Disease of Mental Health, also known as mental health, is related to alcohol-induced mental disorder and drug-induced mental disorder, and has symptoms including agitation, lethargy and forgetful. An important gene associated with Disease of Mental Health is BDNF-AS (BDNF Antisense RNA), and among its related pathways/superpathways are Circadian entrainment and Beta-Adrenergic Signaling. The drugs Paroxetine and Sertraline have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and breast, and related phenotypes are shRNA abundance <= 50% and Decreased DCP1a protein expression and assembly in processing bodies after arsenite stimulation

Disease Ontology : 12 A disease that involves a psychological or behavioral pattern generally associated with subjective distress or disability that occurs in an individual, and which are not a part of normal development or culture.

CDC : 3 Mental health is an important part of overall health and well-being. Mental health includes our emotional, psychological, and social well-being. It affects how we think, feel, and act. It also helps determine how we handle stress, relate to others, and make healthy choices. Mental health is important at every stage of life, from childhood and adolescence through adulthood.

Related Diseases for Disease of Mental Health

Diseases related to Disease of Mental Health via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 488)
# Related Disease Score Top Affiliating Genes
1 alcohol-induced mental disorder 34.1 DRD2 SLC6A3 SLC6A4
2 drug-induced mental disorder 33.8 DRD2 HTR1A HTR2A
3 depression 33.1 BDNF BDNF-AS HTR1A HTR2A SLC6A4
4 eating disorder 33.0 BDNF COMT DRD2 SLC6A3 SLC6A4
5 anxiety 32.9 BDNF COMT HTR1A HTR2A SLC6A4
6 bipolar disorder 32.9 BDNF COMT DRD2 DRD3 HTR1A HTR2A
7 learning disability 32.8 FMR1 MAPT MECP2
8 post-traumatic stress disorder 32.7 APOE BDNF COMT DRD2 HTR2A SLC6A4
9 obsessive-compulsive disorder 32.7 BDNF COMT DRD2 DRD3 DRD4 HTR1A
10 schizophrenia 32.7 BDNF BDNF-AS COMT DRD2 DRD3 DRD4
11 panic disorder 32.7 COMT HTR1A HTR2A SLC6A4
12 major depressive disorder 32.6 APOE BDNF COMT DRD2 DRD3 DRD4
13 schizoaffective disorder 32.6 BDNF COMT DRD2 DRD3 HTR2A SLC6A4
14 attention deficit-hyperactivity disorder 32.4 BDNF COMT DRD2 DRD3 DRD4 FMR1
15 paranoid schizophrenia 32.3 BDNF COMT HTR2A SLC6A4
16 sexual disorder 32.3 HTR1A PDE5A SLC6A4
17 impulse control disorder 32.3 DRD2 DRD3 DRD4
18 pervasive developmental disorder 32.2 BDNF FMR1 MECP2 SLC6A4
19 personality disorder 32.1 BDNF COMT DRD2 DRD4 HTR1A HTR2A
20 specific developmental disorder 32.0 BDNF COMT DRD4 EP300 FMR1 MECP2
21 substance abuse 31.9 BDNF COMT DRD2 DRD3 DRD4 SLC6A3
22 alcoholic psychosis 31.8 DRD2 HTR2A SLC6A3 SLC6A4
23 hypoactive sexual desire disorder 31.7 HTR1A HTR2A
24 schizophreniform disorder 31.6 COMT DRD2
25 autism spectrum disorder 31.5 BDNF FMR1 HTR2A MECP2 SLC6A4
26 autism 31.4 BDNF FMR1 HTR1A HTR2A MECP2 SLC6A4
27 borderline personality disorder 31.4 BDNF COMT HTR1A HTR2A SLC6A4
28 traumatic brain injury 31.2 APOE BDNF COMT DRD2
29 dementia 31.2 APOE BDNF HTR2A MAPT SLC6A3
30 postpartum depression 31.2 BDNF COMT SLC6A4
31 brain injury 31.2 APOE BDNF COMT DRD2 MAPT
32 alcohol abuse 31.2 BDNF DRD2 DRD3 DRD4 HTR2A SLC6A4
33 mental depression 31.1 BDNF COMT HTR1A HTR2A SLC6A4
34 chronic fatigue syndrome 31.0 COMT HTR1A HTR2A SLC6A4
35 generalized anxiety disorder 31.0 BDNF COMT DRD2 HTR1A HTR2A SLC6A4
36 fibromyalgia 30.9 COMT HTR2A SLC6A4
37 tobacco addiction 30.9 COMT DRD2 HTR2A OPRM1 SLC6A3 SLC6A4
38 mood disorder 30.9 BDNF COMT DRD2 DRD3 DRD4 HTR1A
39 vascular dementia 30.9 APOE MAPT SERPINA3
40 anorexia nervosa 30.8 BDNF COMT HCRT HTR2A SLC6A4
41 alexithymia 30.8 COMT DRD2 HTR1A SLC6A4
42 tardive dyskinesia 30.8 COMT DRD2 DRD3 HTR2A
43 bulimia nervosa 30.8 BDNF COMT HTR2A SLC6A4
44 alcohol dependence 30.8 BDNF COMT DRD2 DRD3 DRD4 HTR1A
45 substance dependence 30.7 BDNF DRD2 DRD3 DRD4 OPRM1 SLC6A3
46 pathological gambling 30.7 DRD2 DRD3 DRD4 HTR2A SLC6A3 SLC6A4
47 sleep apnea 30.7 APOE HCRT HTR2A
48 antisocial personality disorder 30.7 COMT DRD2 SLC6A3 SLC6A4
49 oppositional defiant disorder 30.6 COMT DRD2 DRD4 SLC6A3 SLC6A4
50 phobia, specific 30.6 COMT FMR1

Graphical network of the top 20 diseases related to Disease of Mental Health:



Diseases related to Disease of Mental Health

Symptoms & Phenotypes for Disease of Mental Health

UMLS symptoms related to Disease of Mental Health:


agitation, lethargy, forgetful, decrease in appetite, nervousness, feeling jittery, symptoms, alexithymia, increased libido, numbness, psychiatric symptom, hallucinations, auditory, hallucinations, visual, numbness localized, feeling detached, feeling strange, feeling weightless, floating feeling, dejection emotional, depressed reaction, hallucinations, sensory, restless sleep, difficulty sleeping, excitability, depression aggravated, agitation mental, numb mouth, opiate withdrawal symptoms, clouded consciousness, trembling inside, sluggishness

GenomeRNAi Phenotypes related to Disease of Mental Health according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.32 COMT DRD2 DRD3 DRD4 EP300 HTR1A
2 Decreased DCP1a protein expression and assembly in processing bodies after arsenite stimulation GR00203-A 9.26 APOE DRD3 EP300 SLC6A4

MGI Mouse Phenotypes related to Disease of Mental Health:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.4 APOE BDNF COMT DRD2 DRD3 DRD4
2 homeostasis/metabolism MP:0005376 10.28 APOE BDNF COMT DRD2 DRD3 DRD4
3 growth/size/body region MP:0005378 10.23 APOE BDNF DRD2 DRD3 EP300 FMR1
4 endocrine/exocrine gland MP:0005379 10.22 APOE BDNF COMT DRD2 EP300 FMR1
5 cardiovascular system MP:0005385 10.21 APOE COMT DRD2 DRD3 EP300 HCRT
6 nervous system MP:0003631 10.2 APOE BDNF COMT DRD2 DRD3 DRD4
7 integument MP:0010771 10.06 APOE BDNF DRD2 FMR1 MAPT MECP2
8 digestive/alimentary MP:0005381 10.04 APOE BDNF DRD2 DRD3 EP300 HTR2A
9 muscle MP:0005369 9.97 APOE DRD2 EP300 HCRT HTR2A MAPT
10 no phenotypic analysis MP:0003012 9.8 APOE BDNF DRD2 HTR1A MAPT MECP2
11 normal MP:0002873 9.76 BDNF DRD2 EP300 MAPT MECP2 OPRM1
12 respiratory system MP:0005388 9.5 APOE BDNF COMT DRD2 EP300 HCRT
13 taste/olfaction MP:0005394 9.02 APOE BDNF DRD2 MAPT SLC6A3

Drugs & Therapeutics for Disease of Mental Health

Drugs for Disease of Mental Health (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
2
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 79617-96-2 68617
3
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54910-89-3 3386
4
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
5
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 54739-18-3 3404 5324346
6
Trazodone Approved, Investigational Phase 4,Phase 3,Phase 1 19794-93-5 5533
7
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-41-2 439260
8
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-45-6 774
9
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 34841-39-9, 34911-55-2 444
10
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
11
Mirtazapine Approved Phase 4,Phase 2,Phase 3,Not Applicable 61337-67-5, 85650-52-8 4205
12
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 129722-12-9 60795
13
Metformin Approved Phase 4,Phase 3,Not Applicable 657-24-9 14219 4091
14
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113-45-1 4158
15
Donepezil Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 120014-06-4 3152
16
Parathyroid hormone Approved, Investigational Phase 4,Phase 3 9002-64-6
17
Ropinirole Approved, Investigational Phase 4,Phase 2 91374-21-9, 91374-20-8 5095 497540
18
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10118-90-8 5281021
19
Haloperidol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-86-8 3559
20
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
21
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-03-3
22
Methimazole Approved Phase 4 60-56-0 1349907
23
Reboxetine Approved, Experimental Phase 4,Phase 1 98769-81-4, 71620-89-8 65856 123628
24
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 106266-06-2 5073
25
Levonorgestrel Approved, Investigational Phase 4,Phase 3,Phase 1 17489-40-6, 797-63-7 13109
26
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
27
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 53714-56-0 657181 3911
28
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Not Applicable 471-34-1
29
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
30
Tibolone Approved, Investigational Phase 4 5630-53-5
31
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99-66-1 3121
32
Dextroamphetamine Approved, Illicit Phase 4,Phase 2,Phase 1,Not Applicable 51-64-9 5826
33
Guanfacine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 29110-47-2 3519
34
Buspirone Approved, Investigational Phase 4,Phase 1,Phase 2 36505-84-7 2477
35
Acamprosate Approved, Investigational Phase 4,Phase 2 77337-76-9 71158
36
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 16590-41-3 5360515
37
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
38
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 132539-06-1 4585
39
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 554-13-2
40
Oxcarbazepine Approved Phase 4 28721-07-5 34312
41
Coal tar Approved Phase 4,Phase 2,Not Applicable 8007-45-2
42
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 146939-27-7 60854
43
Zidovudine Approved Phase 4,Phase 2,Phase 3,Not Applicable 30516-87-1 35370
44
Abacavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 136470-78-5 441300 65140
45
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3 154598-52-4 64139
46
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 134678-17-4 60825
47
Simvastatin Approved Phase 4,Phase 1 79902-63-9 54454
48
Clozapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5786-21-0 2818
49
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 19982-08-2 4054
50
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54-11-5 942 89594

Interventional clinical trials:

(show top 50) (show all 7975)
# Name Status NCT ID Phase Drugs
1 Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients Unknown status NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
2 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
3 Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile Unknown status NCT02949752 Phase 4 Aripiprazole
4 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
5 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
6 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
7 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
8 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Unknown status NCT02777905 Phase 4
9 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4 Escitalopram
10 Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression Unknown status NCT01390662 Phase 4
11 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
12 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4 Minocycline;placebo
13 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
14 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
15 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
16 Cardiopulmonary Capacity in Elderly With Different Ranges of Serum Thyroid Stimulating Hormone Unknown status NCT01849861 Phase 4 Methimazole
17 The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia Unknown status NCT03080194 Phase 4 paliperidone palmitate;control group
18 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
19 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4 Risperidone
20 Psychological Impact of Amenorrhea in Women With Endometriosis Unknown status NCT02393482 Phase 4 Estroprogestinic therapy (Etinil-estradiol/levonorgestre);Gonadotropin-releasing hormone agonist (Leuprorelin acetate);Add back therapy 1 (tibolone);Add back therapy 2 (calcium carbonate/colecalciferol)
21 Development of a Nationally Scalable Model of Group Prenatal Care to Improve Birth Outcomes: "Expect With Me" Unknown status NCT02169024 Phase 4
22 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
23 Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
24 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
25 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
26 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
27 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
28 Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression Unknown status NCT00106197 Phase 4 Bupropion
29 Diabetes Prevention Program in Schizophrenia [DPPS] Unknown status NCT00182494 Phase 4
30 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
31 Trial for the Treatment of Alcohol Dependence Unknown status NCT00120601 Phase 4 Naltrexone;Acamprosate
32 Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications Unknown status NCT01796132 Phase 4 SSRI/SNRI
33 Preventing Recurrent Gestational Diabetes With Metformin Unknown status NCT02394158 Phase 4 Metformin;placebo
34 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
35 Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
36 Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients Unknown status NCT00842920 Phase 4 Simvastatin;Placebo
37 Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study Unknown status NCT01962402 Phase 4 lorcaserin
38 Memory and Mental Health in Aging Completed NCT02988908 Phase 4 Donepezil;Placebos
39 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Completed NCT01201967 Phase 4
40 The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS Completed NCT01961180 Phase 4 Cipralex;Placebo
41 The Effect of Training on Endothelial Function, Progression of Disease,Inflammation, Heart Rate Variability and Mental Health After Percutaneous Coronary Intervention Completed NCT00469950 Phase 4
42 Driving in Adults With Attention-deficit/Hyperactivity Disorder (ADHD) Before and During Treatment With Atomoxetine Completed NCT00938743 Phase 4 Atomoxetine
43 Preventing Depression Relapse With Mindfulness-Based Cognitive Therapy Completed NCT00183560 Phase 4 Antidepressants;Placebo plus clinical management
44 Switching Antipsychotics: Abrupt Discontinuation Versus Overlap Completed NCT02640300 Phase 4 Clozapine
45 Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness Completed NCT02167620 Phase 4 Metformin;Placebo
46 Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease Completed NCT00800709 Phase 4 Memantine
47 Abuse Liability of Controlled-Release Oxycodone Formulations Completed NCT02101840 Phase 4 Apo-Oxycodone CR®;OxyNEO®;Placebo
48 Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia Completed NCT01850953 Phase 4 Varenicline;Placebo
49 Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients Completed NCT02298985 Phase 4 Curcumin;placebo
50 Electronic Cigarettes in Daily Dependent Smokers Completed NCT02108626 Phase 4 Nicotine;Placebo

Search NIH Clinical Center for Disease of Mental Health

Cochrane evidence based reviews: mental disorders

Genetic Tests for Disease of Mental Health

Anatomical Context for Disease of Mental Health

MalaCards organs/tissues related to Disease of Mental Health:

42
Brain, Testes, Breast, Heart, Bone, Prostate, Lung

Publications for Disease of Mental Health

Articles related to Disease of Mental Health:

(show top 50) (show all 4472)
# Title Authors Year
1
Impact of combat exposure on mental health trajectories in later life: Longitudinal findings from the VA normative aging study. ( 30816736 )
2019
2
A comparison of DSM-5 and DSM-IV agoraphobia in the World Mental Health Surveys. ( 30726581 )
2019
3
Use of mental health services by community-resident adults with DSM-IV anxiety and mood disorders in a violence-prone area: São Paulo, brazil. ( 30856491 )
2019
4
The Effect of the Treatment at a Pain Clinic on the Patients' Assessment of Their Pain Intensity and the Incidence of Mental Disorders in the form of Anxiety, Depression, and Aggression. ( 30781613 )
2019
5
Mental Health Nurses Supporting the Routine Assessment of Anxiety of Older People in Primary Care Settings: Insights from an Australian Study. ( 30605357 )
2019
6
Mental Health in the Cree Peoples of Northern Quebec: Relationships Among Trauma, Familial Psychological Distress, and Mood or Anxiety Disorders. ( 29929388 )
2019
7
Mental Health and Rheumatoid Arthritis: Toward Understanding the Emotional Status of People with Chronic Disease. ( 30886858 )
2019
8
Improved quality of life of patients with rheumatoid arthritis and nonpsychotic mental disorders. ( 30796861 )
2019
9
The Impact of Targeted Rheumatoid Arthritis Pharmacologic Treatment on Mental Health. ( 30688411 )
2019
10
The influence of mental health on Patient-Reported Outcomes Measurement Information System (PROMIS) and traditional outcome instruments in patients with symptomatic glenohumeral arthritis. ( 30552069 )
2019
11
The Costs of High Self-Control in Black and Latino Youth with Asthma: Divergence of Mental Health and Inflammatory Profiles. ( 30818034 )
2019
12
Self-reported asthma diagnosis and mental health: Findings from the Collaborative Psychiatric Epidemiology Surveys. ( 30791347 )
2019
13
Parents' child-related schemas: Associations with children's asthma and mental health. ( 30652916 )
2019
14
Attention-deficit/hyperactivity disorder symptoms and perceived mental health discrimination in adults in the general population. ( 30654318 )
2019
15
Needs, strain, coping, and mental health among caregivers of individuals with autism spectrum disorder: A moderated mediation analysis. ( 30892929 )
2019
16
Parental Perspectives on Psychiatric Comorbidity in Preschoolers With Autism Spectrum Disorders Receiving Publicly Funded Mental Health Services. ( 30914976 )
2019
17
Predictors of mental health and well-being in employed adults with autism spectrum disorder at 12-month follow-up. ( 30675764 )
2019
18
Mental Health and Coping in Parents of Children with Autism Spectrum Disorder (ASD) in Singapore: An Examination of Gender Role in Caring. ( 30706349 )
2019
19
Application of eye trackers for understanding mental disorders: Cases for schizophrenia and autism spectrum disorder. ( 30712295 )
2019
20
Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. ( 30844850 )
2019
21
Metabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia. ( 30747428 )
2019
22
58 Case Report: Clinical Challenges in the Diagnoses and Management of Delirious Mania in a US Veteran with a Mental Health History of Bipolar Disorder. ( 30859980 )
2019
23
Attitudes of Mental Health Staff Toward Patients With Borderline Personality Disorder: An Italian Cross-Sectional Multisite Study. ( 30785861 )
2019
24
Mixed methods evaluation of an educational intervention to change mental health nurses' attitudes to people diagnosed with borderline personality disorder. ( 30830704 )
2019
25
Stigma perpetuation at the interface of mental health care: a review to compare patient and clinician perspectives of stigma and borderline personality disorder. ( 30862201 )
2019
26
Promoting mental health in traumatic brain injury using single-session Behavioural Activation and SMS messaging: A randomized controlled trial. ( 30870102 )
2019
27
Traumatic Brain Injury in the General Population: Incidence, Mental Health Comorbidity, and Functional Impact. ( 30575707 )
2019
28
Traumatic brain injury and hazardous/harmful drinking: Concurrent and single associations with poor mental health and roadway aggression. ( 30611965 )
2019
29
RE: Associations between breast cancer survivorship and adverse mental health outcomes: a systematic review. ( 30629204 )
2019
30
Common mental disorders and bruxism in adults: A Birth Cohort study. ( 30851344 )
2019
31
Capacity building in burns and mental health care. ( 30792033 )
2019
32
Mental health disorders, participation, and bullying in children with cerebral palsy. ( 30710352 )
2019
33
A bio-psycho-social view of cerebral palsy: friendships reduce mental health disorders. ( 30762227 )
2019
34
Implementation of stepped care for patients with chronic fatigue syndrome in community-based mental health care: outcomes at post-treatment and long-term follow-up. ( 30859928 )
2019
35
The Impact of Spirituality and Religiosity on Mental Health and Quality of Life of Patients with Active Crohn's Disease. ( 30911874 )
2019
36
Effects of a primary palliative care intervention on quality of life and mental health in cystic fibrosis. ( 30854795 )
2019
37
Positive mental health and wellbeing in adolescents with cystic fibrosis. ( 30579558 )
2019
38
Positive mental health and wellbeing in adults with cystic fibrosis: A cross sectional study. ( 30579560 )
2019
39
Do interventions that include education on dementia progression improve knowledge, mental health and burden of family carers? A systematic review. ( 30786759 )
2019
40
Early intervention for depression in young people: a blind spot in mental health care. ( 30904117 )
2019
41
Early intervention for depression in young people: a blind spot in mental health care - Authors' reply. ( 30904118 )
2019
42
A Game-Based School Program for Mental Health Literacy and Stigma Regarding Depression (Moving Stories): Protocol for a Randomized Controlled Trial. ( 30869652 )
2019
43
Increased brain entropy of resting-state fMRI mediates the relationship between depression severity and mental health-related quality of life in late-life depressed elderly. ( 30870777 )
2019
44
The effect of mental health screening and referral on symptoms of depression among HIV positive outpatients in Vietnam: Findings from a three-month follow up study. ( 30884957 )
2019
45
Depression Agency-Based Collaborative: Effect of Problem-Solving Therapy on Risk of Common Mental Disorders in Older Adults With Home Care Needs. ( 30795944 )
2019
46
Recognizing maternal mental health disorders: beyond postpartum depression. ( 30694850 )
2019
47
Prevalence of late-life depression and gap in mental health service use across European regions. ( 30658276 )
2019
48
Effect of Mental Health Screening and Integrated Mental Health on Adolescent Depression-Coded Visits. ( 30623684 )
2019
49
Encompassing a global mental health perspective into psychotherapy research: a critique of approaches to measuring the efficacy of psychotherapy for depression. ( 30642409 )
2019
50
Residential transience among US adolescents: association with depression and mental health treatment. ( 30642414 )
2019

Variations for Disease of Mental Health

ClinVar genetic disease variations for Disease of Mental Health:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 LOC730100 NC_000002.12: g.51071313_51109710del38398 deletion no interpretation for the single variant GRCh37 Chromosome 2, 51298451: 51336848
2 LOC730100 NC_000002.12: g.51071313_51109710del38398 deletion no interpretation for the single variant GRCh38 Chromosome 2, 51071313: 51109710
3 LOC730100 NC_000002.12: g.51071313_51109710del38398 deletion no interpretation for the single variant NCBI36 Chromosome 2, 51151955: 51190352
4 LOC730100 NC_000002.12: g.51360327_51400639del40313 deletion no interpretation for the single variant GRCh37 Chromosome 2, 51587465: 51627777
5 LOC730100 NC_000002.12: g.51360327_51400639del40313 deletion no interpretation for the single variant GRCh38 Chromosome 2, 51360327: 51400639
6 LOC730100 NC_000002.12: g.51360327_51400639del40313 deletion no interpretation for the single variant NCBI36 Chromosome 2, 51440969: 51481281

Expression for Disease of Mental Health

Search GEO for disease gene expression data for Disease of Mental Health.

Pathways for Disease of Mental Health

Pathways related to Disease of Mental Health according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 COMT DRD2 DRD3 DRD4 OPRM1 SLC6A3
2
Show member pathways
12.55 BDNF DRD2 DRD3 DRD4 MAPT
3 12.06 BDNF DRD2 EP300 HTR1A
5
Show member pathways
11.77 BDNF DRD2 SLC6A3
6 11.76 APOE COMT FMR1 HCRT HTR1A MAPT
7 11.75 HTR1A HTR2A SLC6A4
8 11.68 DRD3 DRD4 HTR2A
9
Show member pathways
11.66 DRD2 DRD3 DRD4
10 11.65 BDNF EP300 HTR1A HTR2A MECP2 SLC6A4
11
Show member pathways
11.6 DRD2 DRD3 DRD4 HTR1A HTR2A
12 10.99 HTR1A HTR2A SLC6A4
13
Show member pathways
10.91 COMT SLC6A3 SLC6A4

GO Terms for Disease of Mental Health

Cellular components related to Disease of Mental Health according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.88 APOE FMR1 HTR2A MAPT SLC6A3
2 glutamatergic synapse GO:0098978 9.85 APOE DRD2 DRD3 DRD4 HTR2A
3 membrane raft GO:0045121 9.8 MAPT OPRM1 SLC6A3 SLC6A4
4 dendritic spine GO:0043197 9.73 COMT DRD2 FMR1 MAPT
5 postsynapse GO:0098794 9.67 DRD4 FMR1 HCRT MECP2
6 integral component of presynaptic membrane GO:0099056 9.65 DRD2 HTR2A OPRM1 SLC6A3 SLC6A4
7 axon GO:0030424 9.56 BDNF COMT DRD2 FMR1 HTR2A MAPT
8 integral component of postsynaptic membrane GO:0099055 9.55 DRD2 HTR2A OPRM1 SLC6A3 SLC6A4
9 glial cell projection GO:0097386 9.51 FMR1 MAPT
10 dopaminergic synapse GO:0098691 9.5 DRD2 DRD3 SLC6A3
11 dendrite GO:0030425 9.32 APOE BDNF COMT DRD2 DRD4 FMR1
12 plasma membrane GO:0005886 10.3 APOE COMT DRD2 DRD3 DRD4 FMR1
13 integral component of plasma membrane GO:0005887 10.01 DRD2 DRD3 DRD4 HTR1A HTR2A OPRM1

Biological processes related to Disease of Mental Health according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.97 DRD2 EP300 MECP2 SLC6A4
2 response to drug GO:0042493 9.97 COMT DRD2 DRD3 HTR2A SLC6A3 SLC6A4
3 response to ethanol GO:0045471 9.92 DRD2 DRD3 OPRM1 SLC6A3
4 cellular calcium ion homeostasis GO:0006874 9.89 APOE DRD3 DRD4 HTR2A
5 locomotory behavior GO:0007626 9.88 DRD2 DRD3 OPRM1 SLC6A3
6 learning GO:0007612 9.86 COMT DRD3 MECP2
7 synapse assembly GO:0007416 9.86 BDNF DRD2 MECP2
8 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.85 HCRT HTR2A OPRM1
9 sensory perception of pain GO:0019233 9.85 HTR2A MECP2 OPRM1
10 visual learning GO:0008542 9.84 DRD2 DRD3 MECP2
11 excitatory postsynaptic potential GO:0060079 9.84 DRD2 HCRT MECP2 OPRM1
12 response to amphetamine GO:0001975 9.82 DRD2 DRD3 DRD4
13 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.81 DRD4 HTR1A HTR2A
14 long-term memory GO:0007616 9.81 APOE DRD2 MECP2
15 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.81 DRD4 HTR1A HTR2A OPRM1
16 behavioral fear response GO:0001662 9.8 DRD4 HTR1A MECP2
17 response to morphine GO:0043278 9.8 DRD2 DRD3 OPRM1
18 social behavior GO:0035176 9.78 DRD3 DRD4 MECP2 SLC6A4
19 arachidonic acid secretion GO:0050482 9.76 DRD2 DRD3 DRD4
20 temperature homeostasis GO:0001659 9.74 DRD2 HCRT HTR2A
21 dopamine receptor signaling pathway GO:0007212 9.73 DRD2 DRD3 DRD4
22 response to iron ion GO:0010039 9.72 DRD2 SLC6A3
23 synaptic transmission, dopaminergic GO:0001963 9.72 DRD2 DRD3
24 startle response GO:0001964 9.72 DRD2 MECP2
25 vasoconstriction GO:0042310 9.72 HTR1A SLC6A4
26 negative regulation of protein secretion GO:0050709 9.72 DRD2 DRD3 DRD4
27 neurotransmitter biosynthetic process GO:0042136 9.71 SLC6A3 SLC6A4
28 positive regulation of renal sodium excretion GO:0035815 9.71 DRD2 DRD3
29 G protein-coupled receptor internalization GO:0002031 9.71 DRD2 DRD3
30 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.71 DRD3 DRD4
31 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.71 DRD3 OPRM1
32 negative regulation of potassium ion transport GO:0043267 9.7 HCRT HTR2A
33 adenohypophysis development GO:0021984 9.7 DRD2 SLC6A3
34 behavior GO:0007610 9.7 HTR1A HTR2A
35 monoamine transport GO:0015844 9.7 SLC6A3 SLC6A4
36 prepulse inhibition GO:0060134 9.7 DRD2 DRD3 SLC6A3
37 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.69 DRD2 HTR2A
38 serotonin receptor signaling pathway GO:0007210 9.69 HTR1A HTR2A
39 dopamine catabolic process GO:0042420 9.69 COMT SLC6A3
40 internal protein amino acid acetylation GO:0006475 9.68 EP300 MAPT
41 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.66 DRD2 DRD3
42 negative regulation of dopamine receptor signaling pathway GO:0060160 9.66 DRD2 DRD3
43 acid secretion GO:0046717 9.65 DRD2 DRD3
44 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.65 DRD2 DRD4
45 regulation of locomotion involved in locomotory behavior GO:0090325 9.65 DRD2 DRD3
46 memory GO:0007613 9.65 BDNF HTR2A MAPT MECP2 SLC6A4
47 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.63 DRD2 DRD3 DRD4
48 response to cocaine GO:0042220 9.62 DRD2 DRD3 OPRM1 SLC6A3
49 regulation of dopamine metabolic process GO:0042053 9.61 DRD4 HTR1A SLC6A3
50 neurological system process involved in regulation of systemic arterial blood pressure GO:0001976 9.6 DRD2 MECP2

Molecular functions related to Disease of Mental Health according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.95 DRD2 DRD3 DRD4 HTR1A HTR2A OPRM1
2 neurotransmitter receptor activity GO:0030594 9.58 DRD4 HTR1A HTR2A
3 G protein-coupled serotonin receptor activity GO:0004993 9.54 DRD4 HTR1A HTR2A
4 adrenergic receptor activity GO:0004935 9.52 DRD2 DRD3
5 neurotransmitter:sodium symporter activity GO:0005328 9.51 SLC6A3 SLC6A4
6 serotonin binding GO:0051378 9.5 HTR1A HTR2A SLC6A4
7 siRNA binding GO:0035197 9.49 FMR1 MECP2
8 monoamine transmembrane transporter activity GO:0008504 9.46 SLC6A3 SLC6A4
9 lipoprotein particle binding GO:0071813 9.43 APOE MAPT
10 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD2 DRD3 DRD4
11 drug binding GO:0008144 9.35 DRD2 DRD3 DRD4 HTR2A SLC6A3
12 dopamine neurotransmitter receptor activity GO:0004952 9.33 DRD2 DRD3 DRD4
13 dopamine binding GO:0035240 8.92 DRD2 DRD3 DRD4 SLC6A3

Sources for Disease of Mental Health

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....